SAN MATEO, Calif.–(BUSINESS WIRE)–Model N, Inc. (NYSE: MODN), the leader in revenue optimization and compliance, plans to announce financial results for the third quarter of fiscal year 2023 after market close on Tuesday, August 8, 2023. The company also plans to host a conference call that day at 2:00 p.m. PT (5:00 p.m. ET) to review its financial results and business outlook.
The conference call can be accessed by dialing 877-407-4018 from the United States or +1-201-689-8471 internationally with reference to the company name and conference title. A live webcast and replay of the conference call can be accessed from the investor relations page of Model N’s website at investor.modeln.com. Following the completion of the call through 11:59 p.m. ET on August 22, 2023, a telephone replay will be available by dialing 844-512-2921 from the United States or +1-412-317-6671 internationally with recording access code 13735136.
About Model N
Model N is the leader in revenue optimization and compliance for pharmaceutical, medtech and high-tech innovators. Our intelligent platform powers your digital transformation with integrated technology, data, analytics, and expert services that deliver deep insight and control.
Our integrated cloud solution is proven to automate pricing, incentive and contract decisions to scale business profitably and grow revenue. Model N is trusted across more than 120 countries by the world’s leading pharmaceutical, medical technology, semiconductor, and high-tech companies, including Johnson & Johnson, AstraZeneca, Stryker, Seagate Technology, Broadcom, and Microchip Technology. For more information, visit www.modeln.com.
Contacts
Investor Relations Contact:
Carolyn Bass
Market Street Partners
investorrelations@modeln.com
Public Relations
BLASTmedia
modeln@blastmedia.com
Duty Free Meds is proud to introduce a new Zepbound coupon offering to help lower…
Duty Free Meds is proud to introduce a new Zepbound coupon offering to help lower…
Magdalena to explore coca leaf's possible therapeutic benefit for treatment of potentially ADHD or other…
Beloved MedSpa Overcomes Devastating Fire and Challenges to Continue Serving the Bay Area SAN FRANCISCO,…
MIAMI, FL / ACCESSWIRE / December 19, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage…
This submission comes after successful INTERACT meeting with the FDA earlier this year.NLS Pharmaceutics and…